Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

This study is testing whether tirzepatide — a dual GIP/GLP-1 receptor agonist approved for weight loss and type 2 diabetes — can reduce body weight and dampen chronic inflammation in adults living with HIV who are overweight or obese. People with well-controlled HIV on antiretroviral therapy (ART) still carry a disproportionate burden of metabolic disease and low-grade systemic inflammation, even when their virus is suppressed. Researchers at the University of Hawaii are enrolling 12 participants and escalating tirzepatide doses from 2.5 mg to 7.5 mg weekly over 12 weeks, then following participants for 4 additional weeks off the drug. The primary goal is to measure how much body weight changes by week 12; secondary goals include changes in inflammatory markers like IL-6, TNF-α, and CRP, as well as liver fat, liver stiffness, lipids, HbA1c, and circulating monocytes — all relevant to HIV-associated comorbidities. The study is currently recruiting and expects to complete data collection by May 2026. If tirzepatide reduces both adiposity and inflammation in this population, it could open a targeted pharmacological strategy for a group at persistently elevated cardiovascular and metabolic risk. Results from this small cohort will be hypothesis-generating, intended to justify larger randomised trials.

• No results yet — the trial is actively recruiting as of 2025 (ClinicalTrials.gov NCT06935838; expected completion May 2026).
• Primary outcome is change in body weight from baseline at 12 weeks in 12 overweight/obese adults with well-controlled HIV-1 on ART.
• Secondary outcomes include changes in inflammatory markers (IL-6, TNF-α, CRP), monocyte counts, body composition, liver fat content, liver stiffness, lipids, and HbA1c — providing a broad metabolic and immunological readout of tirzepatide's effects in this population.

This is a prospective, single-arm cohort study enrolling 12 overweight or obese adults (≥1 weight-related comorbidity) with well-controlled HIV-1 on ART. Tirzepatide is administered subcutaneously at an initial dose of 2.5 mg once weekly, escalated by 2.5 mg every 4 weeks to a maximum of 7.5 mg. Key assessments occur at baseline and 12 weeks, covering body weight, body composition, liver imaging (fat and stiffness), inflammatory and cardiometabolic biomarkers, and immune cell profiles. A 4-week safety follow-up period off tirzepatide is included after the active treatment phase.

The sample size of 12 is very small and lacks a control arm, making it impossible to attribute changes in inflammation or metabolic markers to tirzepatide rather than regression to the mean, seasonal variation, or behavioural changes. The 12-week active treatment window is relatively short for assessing durable effects on chronic inflammation or body composition remodelling. The study does not appear to stratify by ART regimen type, which may independently influence metabolic and inflammatory profiles. A necessary next step would be a randomised, placebo-controlled trial with larger numbers, longer follow-up, and ART-stratified analyses to establish causality and generalisability across the HIV population.

This trial occupies a distinct niche within the corpus by targeting ART-suppressed HIV as a model of chronic, treatment-resistant low-grade inflammation, complementing rather than overlapping with studies focused on other inflammatory pathways. It parallels [§45], which tests oral NLRP3 inhibition (ruvonoflast) as a pharmacological anti-inflammatory strategy in individuals at elevated cardiovascular risk — both studies treat residual inflammation as a modifiable cardiovascular risk factor, though through entirely different mechanisms (incretin-based metabolic remodelling vs. inflammasome blockade). It also extends the logic of [§30], where vitamin D3 was shown to mitigate glucose-induced oxidative stress and inflammation at a cellular level, suggesting that metabolic intermediaries are tractable anti-inflammatory targets; tirzepatide acts upstream of many of the same pathways by reducing adiposity and improving insulin sensitivity. The immunological angle — specifically monocyte profiling alongside canonical cytokines — adds a dimension relevant to [§113]'s exploration of T-cell senescence and immune dysregulation in chronic inflammatory states, even though the populations and triggers differ substantially.

• Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
  Both studies test pharmacological agents to reduce residual chronic inflammation and cardiovascular risk, but through mechanistically distinct pathways (incretin/metabolic vs. NLRP3 inflammasome inhibition), making direct mechanistic comparison informative.
• 1,25-Dihydroxyvitamin D3 mitigates high glucose-induced oxidative stress, inflammation, and extracellular matrix accumulation in glomerular mesangial cells via the ROS/TXNIP/NLRP3 pathway
  Provides cellular-level evidence that metabolic stress (high glucose, oxidative burden) drives inflammation — directly relevant to understanding why weight loss via tirzepatide might reduce the inflammatory markers this HIV trial is measuring.
• Ligature-induced periodontitis in mice potentially accelerates CD4+ T-cell senescence and exacerbates rheumatoid arthritis
  Explores immune senescence and T-cell dysfunction as downstream consequences of chronic inflammation, offering a conceptual framework for why reducing inflammation in HIV patients may have immunological benefits beyond the metabolic endpoints measured here.
• Effect of methotrexate on endothelial function in psoriasis patients
  Tests an anti-inflammatory drug (methotrexate) on endothelial function in a chronic inflammatory condition (psoriasis), providing a useful parallel for evaluating whether inflammation reduction translates to measurable vascular benefit — a question this HIV trial does not yet address.